Aktuellt
SENASTE
Redeye provides its initial take on Heliospectra’s Q2’23 report, noting that sales surpassed our expectations. However, the order intake was below expectations, but the cost structure remained in line with our estimates. Consequently, we anticipate minor revisions to our near-term forecast and fair value range.
LÄS MER
